Immune-Cell-Based Therapy for COVID-19: Current Status

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2023 Nov 25

PMID 38005826

Authors

Yiyuan Wang

Qinghe Liang

Fengsheng Chen

Jiehuang Zheng

Yan Chen

Ziye Chen

Ruopeng Li

Xiaojuan Li

Affiliations

Soon will be listed here.

Abstract

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic. The interplay between innate and adaptive immune responses plays a crucial role in managing COVID-19. Cell therapy has recently emerged as a promising strategy to modulate the immune system, offering immense potential for the treatment of COVID-19 due to its customizability and regenerative capabilities. This review provides an overview of the various subsets of immune cell subsets implicated in the pathogenesis of COVID-19 and a comprehensive summary of the current status of immune cell therapy in COVID-19 treatment.

Citing Articles

Comprehensive Review of COVID-19: Epidemiology, Pathogenesis, Advancement in Diagnostic and Detection Techniques, and Post-Pandemic Treatment Strategies.

Chung Y, Lam C, Tan P, Tsang H, Wong S Int J Mol Sci. 2024; 25(15).

PMID: 39125722 PMC: 11312261. DOI: 10.3390/ijms25158155.

References

Zhou R, To K, Wong Y, Liu L, Zhou B, Li X . Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses. Immunity. 2020; 53(4):864-877.e5. PMC: 7402670. DOI: 10.1016/j.immuni.2020.07.026. View

Labanieh L, Mackall C . CAR immune cells: design principles, resistance and the next generation. Nature. 2023; 614(7949):635-648. DOI: 10.1038/s41586-023-05707-3. View

Xu X, Jiang W, Chen L, Xu Z, Zhang Q, Zhu M . Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An exploratory clinical trial. Clin Transl Med. 2021; 11(2):e297. PMC: 7839959. DOI: 10.1002/ctm2.297. View

Keller M, Harris K, Jensen-Wachspress M, Kankate V, Lang H, Lazarski C . SARS-CoV-2-specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein. Blood. 2020; 136(25):2905-2917. PMC: 7746091. DOI: 10.1182/blood.2020008488. View

Cottle C, Porter A, Lipat A, Turner-Lyles C, Nguyen J, Moll G . Impact of Cryopreservation and Freeze-Thawing on Therapeutic Properties of Mesenchymal Stromal/Stem Cells and Other Common Cellular Therapeutics. Curr Stem Cell Rep. 2022; 8(2):72-92. PMC: 9045030. DOI: 10.1007/s40778-022-00212-1. View

Meng F, Xu R, Wang S, Xu Z, Zhang C, Li Y . Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial. Signal Transduct Target Ther. 2020; 5(1):172. PMC: 7450163. DOI: 10.1038/s41392-020-00286-5. View

Gil-Bescos R, Ostiz A, Zalba S, Tamayo I, Bandres E, Rojas-de-Miguel E . Potency assessment of IFNγ-producing SARS-CoV-2-specific T cells from COVID-19 convalescent subjects. Life Sci Alliance. 2023; 6(6). PMC: 10027900. DOI: 10.26508/lsa.202201759. View

Shi L, Huang H, Lu X, Yan X, Jiang X, Xu R . Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduct Target Ther. 2021; 6(1):58. PMC: 7873662. DOI: 10.1038/s41392-021-00488-5. View

Lanzoni G, Linetsky E, Correa D, Cayetano S, Alvarez R, Kouroupis D . Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial. Stem Cells Transl Med. 2021; 10(5):660-673. PMC: 8046040. DOI: 10.1002/sctm.20-0472. View

10.

Juarez-Navarro K, Padilla-Camberos E, Diaz N, Miranda-Altamirano A, Diaz-Martinez N . Human Mesenchymal Stem Cells: The Present Alternative for High-Incidence Diseases, Even SARS-Cov-2. Stem Cells Int. 2021; 2020:8892189. PMC: 7769649. DOI: 10.1155/2020/8892189. View

11.

Lee J, Koh J, Yi K, Kim Y, Park S, Kim E . Single-cell transcriptome of bronchoalveolar lavage fluid reveals sequential change of macrophages during SARS-CoV-2 infection in ferrets. Nat Commun. 2021; 12(1):4567. PMC: 8316405. DOI: 10.1038/s41467-021-24807-0. View

12.

Biron C, Nguyen K, Pien G, Cousens L, Salazar-Mather T . Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol. 1999; 17:189-220. DOI: 10.1146/annurev.immunol.17.1.189. View

13.

Seepathomnarong P, Ongarj J, Sophonmanee R, Seeyankem B, Chusri S, Surasombatpattana S . Regulatory T Cells Decreased during Recovery from Mild COVID-19. Viruses. 2022; 14(8). PMC: 9415862. DOI: 10.3390/v14081688. View

14.

Shi L, Yuan X, Yao W, Wang S, Zhang C, Zhang B . Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial. EBioMedicine. 2021; 75:103789. PMC: 8709782. DOI: 10.1016/j.ebiom.2021.103789. View

15.

Nasrollahi H, Talepoor A, Saleh Z, Vakili M, Heydarinezhad P, Karami N . Immune responses in mildly versus critically ill COVID-19 patients. Front Immunol. 2023; 14:1077236. PMC: 9923185. DOI: 10.3389/fimmu.2023.1077236. View

16.

Dilogo I, Aditianingsih D, Sugiarto A, Burhan E, Damayanti T, Sitompul P . Umbilical cord mesenchymal stromal cells as critical COVID-19 adjuvant therapy: A randomized controlled trial. Stem Cells Transl Med. 2021; 10(9):1279-1287. PMC: 8242692. DOI: 10.1002/sctm.21-0046. View

17.

Galvan-Pena S, Leon J, Chowdhary K, Michelson D, Vijaykumar B, Yang L . Profound Treg perturbations correlate with COVID-19 severity. Proc Natl Acad Sci U S A. 2021; 118(37). PMC: 8449354. DOI: 10.1073/pnas.2111315118. View

18.

Lu T, Ma R, Dong W, Teng K, Kollath D, Li Z . Off-the-shelf CAR natural killer cells secreting IL-15 target spike in treating COVID-19. Nat Commun. 2022; 13(1):2576. PMC: 9095674. DOI: 10.1038/s41467-022-30216-8. View

19.

Muthu S, Jeyaraman M, Kotner M, Jeyaraman N, Rajendran R, Sharma S . Evolution of Mesenchymal Stem Cell Therapy as an Advanced Therapeutic Medicinal Product (ATMP)-An Indian Perspective. Bioengineering (Basel). 2022; 9(3). PMC: 8945480. DOI: 10.3390/bioengineering9030111. View

20.

George P, Wells A, Gisli Jenkins R . Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir Med. 2020; 8(8):807-815. PMC: 7228727. DOI: 10.1016/S2213-2600(20)30225-3. View